Testing a new liver disease treatment with common medications

Plain-English translation of NCT07726368 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated September 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage trial testing a new medication called , which is being developed to treat non-alcoholic fatty liver disease. The study will see how this medication works in the body when taken together with one of two common medicines that people often take for other health conditions. Researchers want to make sure the medication is safe and doesn't cause unexpected problems when combined with these other drugs.

Non-alcoholic fatty liver disease is becoming more common worldwide and can lead to serious liver damage over time. This trial exists to understand whether this medication could be a helpful new treatment, and to make sure it's safe to use alongside medicines people may already be taking.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old
you are in good overall health with no serious heart, lung, liver, kidney, or mental health conditions in the past 5 years
you have not taken any prescription or over-the-counter medications for at least 7 days before starting the study

You likely don't qualify if…

you have a history of serious liver, kidney, heart, or mental health problems
you are allergic to any of the study medications or have had severe drug allergies in the past
you have a history of muscle problems related to statin medications or unexplained muscle pain
you drink more than 10 alcoholic drinks per week or more than 4 drinks in one day
you have had recent surgery or hospitalization within 3 months, or have surgery planned during the study

What participation looks like

You would visit the research center for a study that takes place over two separate periods. You would take the new medication along with either one common heart medication or one common anti-inflammatory medication, depending on which group you're assigned to. The study involves blood tests and other routine health checks to monitor how your body responds to the combination of medications. The whole process is designed to be completed over several weeks.

AI-generated summary from trial data · Sep 15, 2026 · Not medical advice

Trial locations(1 site)

Australia

Nucleus Network Pty Ltd, Melbourne, Victoria